GNE-477_1032754-81-6_DataSheet_MedChemExpress
常用荧光染料探针列表
这是来自于Salk的一个比较全的荧光染料列表，这些荧光染料可广泛用于流式细胞术以及荧光显微镜技术，汇集了各种荧光染料的特性，方便大家查找。
可根据实际所用的检测平台、染料的最大激发光波长和最大发射光波长来选择合适的荧光染料用于实验。
请注意这上面所显示的颜色可能会由于所用浏览器不同而有所不同，他们只是一个与实际颜色的近似值。
Ex: Peak excitation wavelength (nm)
Em: Peak emission wavelength (nm)
QY: Quantum yield
BR: Brightness; Extinction coefficient * Quantum yield / 1000 PS: Photostability; time to 50% brightness (sec)
光色波长λ(nm)代表波长
红（Red）780～630700
橙（Orange）630～600620
黄（Yellow）600～570580 绿（Green）570～500550 青（Cyan）500～470500 蓝（Blue）470～420470 紫（Violet）420～380420。
致癌染料检测DIN 54231
致癌染料检测DIN 54231 致癌染料测试DIN 54231Allergenous disperse dyes 致敏性分散染料 HPLC-MS , DIN 54231Carcinogen dyes 致癌染料 HPLC-MS , DIN 54231一、致敏性分散染料Allergenous disperse致敏染料是指某些会引起人体或动物的皮肤、黏膜或呼吸道过敏的染料。
人体吸入性的过敏主要集中于呼吸道和粘膜，部分活性染料（可分为颗粒状和液状）可造成此类致敏。
目前致敏染料共发现27种。
在国际知名生态安全规范Oeko-Tex Standard 100的2008版中，将其中的20种致敏性分散染料列为生态纺织品的监控项目，下表中1#~20#，并增加了另外两种致敏染料，21#和22#。
这些染料主要用于聚酯、聚酰胺和醋酯纤维的染色，其中的17种为早期用于醋酸纤维的分散染料。
欧盟于2002年5月推出的Eco-Label 标签标准规定：该标准所列出的17种染料（比Oeko-Tex Standard 100少了3种：C.I. 分散蓝1、C.I. 分散棕1和C.I. 分散黄3），并规定当染色纺织品的耐汗渍色牢度（酸性和碱性）低于4级时，不得使用。
了解其他相关及检测请进个人主页禁用的致敏染料编号染料英文名称染料中文名称CAS No.1# Disperse Blue 1 分散蓝1 2475-45-82# Disperse Blue 3 分散蓝3 2475-46-93# Disperse Blue 7 分散蓝7 3179-90-64# Disperse Blue 26 分散蓝26 3860-63-75# Disperse Blue 35 分散蓝35 12222-75-26# Disperse Blue 102 分散蓝102 69766-79-67# Disperse Blue 106 分散蓝106 12223-01-78# Disperse Blue 124 分散蓝124 61951-51-79# Disperse Brown 1 分散棕1 23355-64-810# Disperse Orange 1 分散橙 1 2581-69-311# Disperse Orange 3 分散橙3 730-40-512# Disperse Orange 37/76 分散橙37/76 13301-61-613# Disperse Red 1 分散红1 2872-52-814# Disperse Red 11 分散红11 2872-48-215# Disperse Red 17 分散红17 3179-89-316# Disperse Yellow 1 分散黄1 119-15-317# Disperse Yellow 3 分散黄3 2832-40-818# Disperse Yellow 9 分散黄 9 6373-73-519# Disperse Yellow 39 分散黄39 12236-29-220# Disperse Yellow 49 分散黄49 54824-37-221# Disperse Yellow 23 分散黄23 6250-23-322# Disperse Orange 149 分散橙149 85136-74- 9国际上目前对纺织品上限用致敏性分散染料检出的限定值，不同的买家所制订的合格性评定标准存在一些差异。
BFH772_DataSheet_MedChemExpress
Inhibitors, Agonists, Screening Libraries Data SheetBIOLOGICAL ACTIVITY:BFH772 is a potent oral VEGFR2 inhibitor, which is highly effective at targeting VEGFR2 kinase with an IC 50 value of 3 nM.IC50 & Target: IC50: 2.7±0.9 nM (hVEGFR2), 1.5±0.53 μM (mVEGFR2), 1.7±0.36 μM (hVEGFR1), 1.1±0.29 μM (hVEGFR3)[1]In Vitro: BFH772 is highly selective; apart from inhibiting VEGFR2 at 3 nM IC 50, it also targets B–RAF, RET, and TIE–2, albeit with atleast 40–fold lower potency. BFH772 is inactive (IC 50>10 μM; >2 μM for cKIT) against all other tyrosine specific– andserine/threonine–specific protein kinases tested. BFH772 inhibits VEGFR2 with IC 50 of 4.6±0.6 nM in CHO cells. BFH772 inhibits VEGFR2 with IC 50 of 3 nM in HUVEC cells. BFH772 inhibits the ligand induced autophosphorylation of RET, PDGFR, and KIT kinases,with IC 50 values ranging between 30 and 160 nM. BFH772 is selective (IC 50 values >0.5 μM) against the kinases of EGFR, ERBB2,INS–R, and IGF–1R and against the cytoplasmic BCR–ABL kinase. IC 50 of BFH772 (<0.01 nM, n=2) demonstrates that they abrogated VEGF induced proliferation at remarkably low nM concentrations [1].In Vivo: BFH772 at 3 mg/kg orally dosed once per day potently inhibits melanoma growth (by 54–90% for primary tumor and71–96% for metastasis growth) as depicted by treatment to control ratios. Dose–response curves of BFH772 at 0.3, 1, and 3 mg/kg demonstrate that even at the lowest concentrations, this naphthalene–1–carboxamide inhibits VEGF induced tissue weight and TIE–2 levels but only reaches statistical significance at 1 mg/kg and above [1].PROTOCOL (Extracted from published papers and Only for reference)Kinase Assay:[1]In vitro kinase assay is based on a filter binding assay, using the recombinant GST–fused kinase domainsexpressed in baculovirus and purified over glutathione–sepharose, γ–[33P]ATP as the phosphate donor, and poly(Glu:Tyr 4:1) peptide as the acceptor. Each GST–fused kinase is incubated under optimized buffer conditions [20 mM Tris–HCl buffer (pH 7.5), 1–3 mM MnCl 2, 3–10 mM MgCl 2, 3–8 μg/mL poly(Glu:Tyr 4:1), 0.25 mg/mL polyethylene glycol 20000, 8 μM ATP, 10 μM sodium vanadate, 1mM DTT] and 0.2 μCi γ–33P ATP in a total volume of 30 μL in the presence or absence of a test substance for 10 min at ambient temperature. The reaction is stopped by adding 10 mL of 250 mM EDTA. Using a 384–well filter system, half the volume istransferred onto an Immobilon–polyvinylidene difluoride membrane. The membrane is then washed extensively and dried, and scintillation counting is performed. IC 50s for compounds are calculated by linear regression analysis of the percentage inhibition [1].Cell Assay: BFH772 is dissolved in DMSO (10 mM) and stored, and then diluted with appropriate medium before use [1]. [1]DifferentBa/F3 cell lines rendered IL–3 independent by transduction with various constitutively active tyrosine kinases are grown in RPMI 1640 medium containing 10% fetal calf serum. For maintenance of parental Ba/F3 cells, the medium is additionally supplemented with 10 ng/mL interleukin–3 (IL–3). For proliferation assays, Ba/F3 cells are seeded on 96–well plates in triplicates at 10000 cells per well and incubated with various concentrations of compounds for 72 h followed by quantification of viable cells using a resazurin sodium salt dye reduction readout (commercially known as Alamar Blue assay). IC 50s are determined with the XLFit Excel Add–In using a four–parameter dose response model [1].Animal Administration: BFH772 is prepared in PEG200 100% (Mice)[1].Product Name:BFH772Cat. No.:HY-100419CAS No.:890128-81-1Molecular Formula:C 23H 16F 3N 3O 3Molecular Weight:439.39Target:VEGFR Pathway:Protein Tyrosine Kinase/RTK Solubility:DMSO: 7.75 mg/mLBFH772 is dissolved in N–methyl pyrrolidone/polyethylene glycol200 (30:70, v/v) (Rat)[1].[1]Mice[1]Female FVB mice weighing between 18 and 20 g are housed in groups of six. Porous chambers containing VEGF (2 μg/mL) in 0.5 mL of 0.8% w/v agar (containing heparin, 20 U/mL) are implanted subcutaneously in the flank of the mice (n=6 per group). VEGF induces the growth of vascularized tissue around the chamber. This response is dose–dependent and can be quantified by measuring the weight and TIE–2 levels of the tissue. Mice are treated either orally once daily with compounds or vehicle (PEG200 100%, 5 mL/kg) starting4–6 h before implantation of the chambers and continuing for 4 days. The animals are sacrificed for measurement of the vascularized tissues 24 h after the last dose. Tissue weight is taken and then a lysate prepared for TIE–2 ELISA analysis .Rat[1]Catheters are implanted into the femoral artery and vein of na?ve female rats strain OFA for BFH772, and BAW2881, or in the jugular vein and femoral artery in female Sprague–Dawley rats for compounds 4, 9, and 10. Animals are allowed to recover for 96 h and are housed in single cages with free access to food and water throughout the experiment. Female OFA rats received 2.5 mg/kg ofBAW2881 dissolved in ethanol/dimethylisosorbide/polyethylene glycol400/D5W (10/15/35/40 v/v) or 1 mg/kg of BFH772 dissolved in N–methyl pyrrolidone/polyethylene glycol200 (30:70, v/v) via injection into the femoral vein. D5W is glucose 5%/water (v/v). Oral administration: BAW2881 and BFH772 are formulated as a micronized suspension (dissolved/suspended in 0.5% carboxymethyl cellulose in distilled water) and administered by gavage to female OFA rats to deliver a dose of 25 mg/kg for BAW2881 or 3 mg/kg BFH772 (n=4 rats per group). For compounds 4, 9, and 10, female Sprague–Dawley rats at 8 weeks of age received an intraveno References:[1]. Bold G, et al. A Novel Potent Oral Series of VEGFR2 Inhibitors Abrogate Tumor Growth by Inhibiting Angiogenesis. J Med Chem. 2016 Jan 14;59(1):132–46.Caution: Product has not been fully validated for medical applications. For research use only.Tel: 609-228-6898 Fax: 609-228-5909 E-mail: tech@Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA。
GENMED线粒体功能詹纳斯绿B染色试剂盒产品说明书范文(中文版)
GENMED线粒体功能詹纳斯绿B染色试剂盒产品说明书范文(中文版)GMS10015v.A主要用途GENMED线粒体功能詹纳斯绿B染色试剂是一种旨在通过一种毒性较小的碱性染料特异性地使具有活性功能的线粒体呈现蓝绿色，从而判断线粒体功能的完整性的权威而经典的技术方法。
该技术由大师级科学家精心研制、成功实验证明的。
其适用于各种线粒体（动物、人体、植物、昆虫等）制备物的功能检测。
产品严格无菌，即到即用，活体检测，操作简捷，性能稳定。
技术背景线粒体是细胞中重要的细胞器，其主要功能是提供细胞内各种物质代谢所需要的能量。
线粒体大量存在于代谢旺盛的细胞中，如动物的心肌、肝、肾等器官和组织的细胞中。
大量制备线粒体就是从这些器官组织中提取，或从组织培养细胞中提取。
在光学显微镜下线粒体呈现为颗粒状、棒状或弯曲细线。
詹纳斯绿B（JanugreenB），是一种毒性较小的碱性染料。
它可以对活细胞进行直接染色，在细胞质内可以看到被染成蓝绿色的线状或颗粒小体的线粒体。
线粒体所以能显示出蓝绿色，是由于线粒体中具有细胞色素氧化酶系统，它是染料始终处于氧化状态呈蓝绿色，而在周围的细胞质中的染料被还原呈无色。
产品内容毫升毫升毫升份保存方式保存在－20℃冰箱里；GENMED染色液(ReagentB)，避免光照；有效保证6月用户自备毫升离心管：用于线粒体染色的容器光学显微镜：用于线粒体染色观察分析实验步骤实验开始前，将℃冰箱里的试剂盒中的GENMED染色液（ReagentB）置于冰槽里融化，并放在暗室里。
然后进行下列操作。
一、纯化线粒体染色1．从纯化的线粒体样品中移出至微升（含细胞中提取的线粒体）到新的预冷的毫升离心管，置于冰槽里（注意：线粒体须均匀分布，没有聚集成团）2．加入等量微升的GENMED染色液（ReagentB），轻柔混匀3．放进暗室里，在室温下孵育1分钟4．即刻移取微升到载玻片上，放上盖玻片5．在光学显微镜油镜下进行观察：功能完整的线粒体呈现蓝绿色圆形或椭圆形颗粒（注意：可见蓝绿色渐渐变淡现象）6．篮绿色强度显著减弱或呈现无色，表明线粒体细胞色素氧化酶系统功能不全或功能丧失二、活体细胞染色1．将待测细胞（某细胞）移入到1.5毫升离心管2．放进微型台式离心机离心1分钟，速度为500g（或2000RPM；例如eppendorf5415）3．小心抽去上清液4．加入微升GENMED清理液（ReagentC）或GENMED保存液（ReagentA）5．加入微升GENMED染色液（ReagentB），充分混匀6．放进暗室里，在冰槽里孵育分钟7．即刻移取微升到载玻片上，放上盖玻片8．在光学显微镜油镜下进行观察：功能完整的线粒体呈现蓝绿色线状或颗粒小体9．篮绿色强度显著减弱或呈现无色，表明线粒体细胞色素氧化酶系统功能不全或功能丧失注意事项1．本产品为20次（活体细胞）或400次（纯化线粒体）操作2．所有操作均须无菌状态下进行3．线粒体样品操作须在低温下进行，且操作快速4．操作时，须戴手套5．建议染色完成后，即刻进行显微镜观察分析6．孵育时，须避免光照7．本公司提供系列线粒体试剂产品质量标准1．本产品经鉴定性能长期稳定2．本产品经鉴定显色清晰使用承诺友情提醒IFITDOESN’TWORK，RECHECKYOURE某PERIMENTTOSEEWHATYOUDIDWRONG。
Gelucire-14-44-SDS-MedChemExpress
Inhibitors, Agonists, Screening LibrariesSafety Data Sheet Revision Date:Nov.-23-2018Print Date:Nov.-23-20181. PRODUCT AND COMPANY IDENTIFICATION1.1 Product identifierProduct name :Gelucire 14/44Catalog No. :HY-Y1892CAS No. :121548-04-71.2 Relevant identified uses of the substance or mixture and uses advised againstIdentified uses :Laboratory chemicals, manufacture of substances.1.3 Details of the supplier of the safety data sheetCompany:MedChemExpress USATel:609-228-6898Fax:609-228-5909E-mail:sales@1.4 Emergency telephone numberEmergency Phone #:609-228-68982. HAZARDS IDENTIFICATION2.1 Classification of the substance or mixtureNot a hazardous substance or mixture.2.2 GHS Label elements, including precautionary statementsNot a hazardous substance or mixture.2.3 Other hazardsNone.3. COMPOSITION/INFORMATION ON INGREDIENTS3.1 SubstancesSynonyms:NoneFormula:N/AMolecular Weight:N/ACAS No. :121548-04-74. FIRST AID MEASURES4.1 Description of first aid measuresEye contactRemove any contact lenses, locate eye-wash station, and flush eyes immediately with large amounts of water. Separate eyelids with fingers to ensure adequate flushing. Promptly call a physician.Skin contactRinse skin thoroughly with large amounts of water. Remove contaminated clothing and shoes and call a physician.InhalationImmediately relocate self or casualty to fresh air. If breathing is difficult, give cardiopulmonary resuscitation (CPR). Avoid mouth-to-mouth resuscitation.IngestionWash out mouth with water; Do NOT induce vomiting; call a physician.4.2 Most important symptoms and effects, both acute and delayedThe most important known symptoms and effects are described in the labelling (see section 2.2).4.3 Indication of any immediate medical attention and special treatment neededTreat symptomatically.5. FIRE FIGHTING MEASURES5.1 Extinguishing mediaSuitable extinguishing mediaUse water spray, dry chemical, foam, and carbon dioxide fire extinguisher.5.2 Special hazards arising from the substance or mixtureDuring combustion, may emit irritant fumes.5.3 Advice for firefightersWear self-contained breathing apparatus and protective clothing.6. ACCIDENTAL RELEASE MEASURES6.1 Personal precautions, protective equipment and emergency proceduresUse full personal protective equipment. Avoid breathing vapors, mist, dust or gas. Ensure adequate ventilation. Evacuate personnel to safe areas.Refer to protective measures listed in sections 8.6.2 Environmental precautionsTry to prevent further leakage or spillage. Keep the product away from drains or water courses.6.3 Methods and materials for containment and cleaning upAbsorb solutions with finely-powdered liquid-binding material (diatomite, universal binders); Decontaminate surfaces and equipment by scrubbing with alcohol; Dispose of contaminated material according to Section 13.7. HANDLING AND STORAGE7.1 Precautions for safe handlingAvoid inhalation, contact with eyes and skin. Avoid dust and aerosol formation. Use only in areas with appropriate exhaust ventilation.7.2 Conditions for safe storage, including any incompatibilitiesKeep container tightly sealed in cool, well-ventilated area. Keep away from direct sunlight and sources of ignition.Recommended storage temperature:Pure form-20°C 3 years4°C 2 yearsIn solvent-80°C 6 months-20°C 1 monthShipping at room temperature if less than 2 weeks.7.3 Specific end use(s)No data available.8. EXPOSURE CONTROLS/PERSONAL PROTECTION8.1 Control parametersComponents with workplace control parametersThis product contains no substances with occupational exposure limit values.8.2 Exposure controlsEngineering controlsEnsure adequate ventilation. Provide accessible safety shower and eye wash station.Personal protective equipmentEye protection Safety goggles with side-shields.Hand protection Protective gloves.Skin and body protection Impervious clothing.Respiratory protection Suitable respirator.Environmental exposure controls Keep the product away from drains, water courses or the soil. Cleanspillages in a safe way as soon as possible.9. PHYSICAL AND CHEMICAL PROPERTIES9.1 Information on basic physical and chemical propertiesAppearance White to off-white (Oil)Odor No data availableOdor threshold No data availablepH No data availableMelting/freezing point No data availableBoiling point/range No data availableFlash point No data availableEvaporation rate No data availableFlammability (solid, gas)No data availableUpper/lower flammability or explosive limits No data availableVapor pressure No data availableVapor density No data availableRelative density No data availableWater Solubility No data availablePartition coefficient No data availableAuto-ignition temperature No data availableDecomposition temperature No data availableViscosity No data availableExplosive properties No data availableOxidizing properties No data available9.2 Other safety informationNo data available.10. STABILITY AND REACTIVITY10.1 ReactivityNo data available.10.2 Chemical stabilityStable under recommended storage conditions.10.3 Possibility of hazardous reactionsNo data available.10.4 Conditions to avoidNo data available.10.5 Incompatible materialsStrong acids/alkalis, strong oxidising/reducing agents.10.6 Hazardous decomposition productsUnder fire conditions, may decompose and emit toxic fumes.Other decomposition products - no data available.11.TOXICOLOGICAL INFORMATION11.1 Information on toxicological effectsAcute toxicityClassified based on available data. For more details, see section 2Skin corrosion/irritationClassified based on available data. For more details, see section 2Serious eye damage/irritationClassified based on available data. For more details, see section 2Respiratory or skin sensitizationClassified based on available data. For more details, see section 2Germ cell mutagenicityClassified based on available data. For more details, see section 2CarcinogenicityIARC: No component of this product present at a level equal to or greater than 0.1% is identified as probable, possible or confirmed human carcinogen by IARC.ACGIH: No component of this product present at a level equal to or greater than 0.1% is identified as a potential or confirmed carcinogen by ACGIH.NTP: No component of this product present at a level equal to or greater than 0.1% is identified as a anticipated or confirmed carcinogen by NTP.OSHA: No component of this product present at a level equal to or greater than 0.1% is identified as a potential or confirmed carcinogen by OSHA.Reproductive toxicityClassified based on available data. For more details, see section 2Specific target organ toxicity - single exposureClassified based on available data. For more details, see section 2Specific target organ toxicity - repeated exposureClassified based on available data. For more details, see section 2Aspiration hazardClassified based on available data. For more details, see section 212. ECOLOGICAL INFORMATION12.1 ToxicityNo data available.12.2 Persistence and degradabilityNo data available.12.3 Bioaccumlative potentialNo data available.12.4 Mobility in soilNo data available.12.5 Results of PBT and vPvB assessmentPBT/vPvB assessment unavailable as chemical safety assessment not required or not conducted.12.6 Other adverse effectsNo data available.13. DISPOSAL CONSIDERATIONS13.1 Waste treatment methodsProductDispose substance in accordance with prevailing country, federal, state and local regulations.Contaminated packagingConduct recycling or disposal in accordance with prevailing country, federal, state and local regulations.14. TRANSPORT INFORMATIONDOT (US)This substance is considered to be non-hazardous for transport.IMDGThis substance is considered to be non-hazardous for transport.IATAThis substance is considered to be non-hazardous for transport.15. REGULATORY INFORMATIONSARA 302 Components:No chemicals in this material are subject to the reporting requirements of SARA Title III, Section 302.SARA 313 Components:This material does not contain any chemical components with known CAS numbers that exceed the threshold (De Minimis) reporting levels established by SARA Title III, Section 313.SARA 311/312 Hazards:No SARA Hazards.Massachusetts Right To Know Components:No components are subject to the Massachusetts Right to Know Act.Pennsylvania Right To Know Components:No components are subject to the Pennsylvania Right to Know Act.New Jersey Right To Know Components:No components are subject to the New Jersey Right to Know Act.California Prop. 65 Components:This product does not contain any chemicals known to State of California to cause cancer, birth defects, or anyother reproductive harm.16. OTHER INFORMATIONCopyright 2018 MedChemExpress. The above information is correct to the best of our present knowledge but does not purport to be all inclusive and should be used only as a guide. The product is for research use only and for experienced personnel. It must only be handled by suitably qualified experienced scientists in appropriately equipped and authorized facilities. The burden of safe use of this material rests entirely with the user. MedChemExpress disclaims all liability for any damage resulting from handling or from contact with this product.Caution: Product has not been fully validated for medical applications. For research use only.Tel: 609-228-6898 Fax: 609-228-5909 E-mail: tech@Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA。
体内组织成像近红外荧光染料DIR（荧光载体）
FITC-PEG-NH2FITC-PEG-COOHFITC-PEG-MALFITC-PEG-NHSFITC-PEG-BiotinFITC-Poly-L-lysineFITC-PLLFITC-dextranFITC-CM-dextranRhoB-PEG-NH2RhoB-PEG-COOHRhoB-PEG-MALRhoB-PEG-NHSRhoB-PEG-BiotinRhoB-Hyaluronic acidCY3-PEG-NH2CY3-PEG-COOH CY3-PEG-MAL CY3-PEG-NHS CY3-PEG-Biotin CY5-PEG-NH2CY5-PEG-COOH CY5-PEG-MAL CY5-PEG-NHS CY5-PEG-Biotin DSPE-PEG-CY5DSPE-PEG-CY7 FITC-Hyaluronic acid 5-FAM Alkyne 5-FAM Azide6-Carboxy Fluorescein; 6-FAM5(6)Carboxy fluorescein; 5(6)-FAM5-Carboxyfluorescein succinimidyl ester; 5-FAM, SE5-Carboxytetramethylrhodamine; 5-TAMRA5(6)-Carboxytetramethylrhodamine succinimidyl ester;5(6)-TAMRA, SE5-Carboxy-X-rhodamine; 5-ROX6-Carboxy-X-rhodamine; 6-ROX5(6)-Carboxy-X-rhodamine; 5(6)-ROX5(6)-Aminofluorescein5(6)-Carboxyfluorescein diacetate5-AminofluoresceinFluorescein isothiocyanate6-Carboxy-X-Rhodamine ，SE (NHS) 6-羧基-X-罗丹明琥珀酰亚胺酯5-TAMRA-Osu 5-羧基四甲基罗丹明琥珀酰亚胺酯体内组织成像近红外荧光染料DIR （荧光载体）体内组织成像近红外荧光染料DIR （荧光载体）纳⽶医学⽹主要从事纳⽶医药相关的技术开发与服务，公司长期专注于⽣物纳⽶原料供应，纳⽶载体系统构建服务（包括各类纳⽶粒、脂质体、胶束等）的全⽅位医学应⽤与技术开发，并已在基因疫苗、蛋⽩药物、常规化药、活体造影剂的纳⽶载体构建及优化⽅⾯积累了⼤量的数据模型与丰富的研究经验。
GN-ID 鉴定条使用说明书
HK-MID革兰氏阴性杆菌生化鉴定系统(HK-MID-64GN-ID A)(HK-MID-65GN-ID B)使用说明书广东环凯微生物科技有限公司广东省微生物研究所HK-MID-GN鉴定条使用流程快速浏览：GN A GN A+B GN A+B 氧化酶阴性阴性阳性接种物挑取1个菌落至3ml盐水挑取1个菌落至5ml盐水挑取1个菌落至5ml盐水（若为放线杆菌属或巴斯德氏菌属，则在菌悬液中加入无菌马血清1滴/ml）接种量每个反应管加3-4滴菌悬液（约100微升）每个反应管加3-4滴菌悬液（约100微升）每个反应管加3-4滴菌悬液（约100微升）矿物油覆盖管1－赖氨酸管2－鸟氨酸管3－硫化氢管1、2、3；管20－阿拉伯糖管24－精氨酸管1、2、3；管24－精氨酸培养时间18-24小时18-24小时48小时培养温度35-37℃35-37℃35-37℃（若为荧光假单胞菌，则为25℃）初读结果添加配套试剂管8（吲哚）：加2滴Kovac试剂，2分钟内记录结果；管10（VP）：加一滴VPⅠ和1滴VPⅡ，15-30分钟后记录结果；管12（TDA）：加1滴TDA试剂，立刻记录结果同GN A；明胶在24小时记录结果；管24（精氨酸）：黄色－阴性，绿/蓝色－阳性同GN A明胶在48小时记录结果，管24（精氨酸）：黄－阴性，蓝色－阳性记录最后结果，并在MID软件上读取结果注：在反应小管上部有黑色圈，表示培养前需用矿物油覆盖；有绿色圈，表示培养后需要添加配套试剂。
产品介绍：GN-ID鉴定系统包括两种独立的鉴定条，即GN A和GN B，GN A是用来鉴定氧化酶阴性、硝酸盐阳性、发酵葡萄糖的大多数肠杆菌科细菌，而GN B需要与GN A共同使用，而非单独使用，GN A+B主要用来鉴定非苛养革兰氏阴性杆菌（包括氧化酶阴性和阳性菌），共包括28个属（参照名录表）。
原理：GN A和GN B鉴定条均分别由12个含干燥培养基的小管组成。
这些测定管用细菌悬浮液接种，培养一定时间后，通过代谢作用产生颜色的变化，或是加入配套试剂后变色，从而来判定结果。
CFDA SE (细胞增殖示踪荧光探针) 说明书
CFDA SE (细胞增殖示踪荧光探针) 产品编号产品名称包装C1031 CFDA SE (细胞增殖示踪荧光探针) 5mg产品简介：CFDA SE 的全称为Carboxyfluorescein diacetate, succinimidyl ester ，是一种近年来被广泛应用的细胞增殖检测用荧光探针，也可以用于细胞的荧光示踪。
基于CFDA SE 荧光标记的细胞增殖检测和[3H]-thymidine 掺入、BrdU 标记获得的检测结果完全一致，但同时可以提供更多的细胞增殖信息。
使用CFDA SE 检测可以提供整个细胞群中有多少比例的细胞分裂了1次、2次或更多次数，同时如果和其它荧光探针联用，可以获取不同分裂次数细胞的其它相关信息。
CFDA-SE 的分子式为C 29H 19NO 11，分子量为557.47，CAS number 为150347-59-4。
CFDA SE 可以通透细胞膜，进入细胞后可以被细胞内的酯酶(esterase)催化分解成CFSE ，CFSE 可以偶发性地(spontaneously)并不可逆地和细胞内蛋白的Lysine 残基或其它氨基发生结合反应，并标记这些蛋白。
在加入荧光探针CFDA SE 后大约24小时，即可充分标记细胞。
被CFDA SE 标记的非分裂细胞的荧光非常稳定，稳定标记的时间可达数个月。
CFDA SE 标记细胞的荧光非常均一，比以前使用的其它细胞示踪荧光探针例如PKH26的荧光更加均一，并且分裂后的子代细胞的荧光分配也更均匀。
由于CFDA SE 标记细胞的荧光非常均匀和稳定，每分裂一次子代细胞的荧光会减弱一半，这样通过流式细胞仪检测就可以检测出没有分裂的细胞，分裂一次的细胞(1/2的荧光强度)，分离两次的细胞(1/4的荧光强度)，分裂三次的细胞(1/8的荧光强度)以及类似的其它分裂次数的细胞。
采用CFDA SE 通过流式细胞仪检测获得的检测结果参考右图。
每一个峰代表一种分裂次数的细胞，从右至左的峰通常依次为分裂0次、1次、2次、3次等次数的细胞。
GNE-477-LCMS-16355-MedChemExpress
=====================================================================Acq. Operator : Li Shan(LCMS-02) Seq. Line : 13Acq. Instrument : HY-LCMS-02 Location : P1-B-01Injection Date : 5/29/2015 10:18:18 AM Inj : 1Inj Volume : 3.000 µlAcq. Method : D:\AGLIENT 1260\DATA\20150529\20150529 2015-05-29 09-24-57\100-1000MS+3MIN- 1.5_(0.02%FA).MLast changed : 5/29/2015 9:24:57 AM by Li Shan(LCMS-02)Analysis Method : D:\AGLIENT 1260\METHOD\WASH-COL2-5MIN.M Last changed : 5/29/2015 12:44:14 PM by Li Shan(LCMS-02) (modified after loading)Catalo No : HY-11042 Batch#16355 A-RP-132Additional Info : Peak(s) manually integratedmin0.511.522.53mAU 02004006008001000 DAD1 C, Sig=254,4 Ref=off (D:\AGLIENT...60\DATA\20150529\20150529 2015-05-29 09-24-57\BIZ2015-529-DJL2.D)1.4991.6721.8521.9702.157 2.195===================================================================== Area Percent Report =====================================================================Sorted By : Signal Multiplier : 1.0000Dilution : 1.0000Do not use Multiplier & Dilution Factor with ISTDsSignal 1: DAD1 C, Sig=254,4 Ref=offPeak RetTime Type Width Area Height Area # [min] [min] [mAU*s] [mAU] %----|-------|----|-------|----------|----------|--------| 1 1.499 MM 0.0607 17.26494 4.73990 0.4467 2 1.672 MM 0.0509 3805.04468 1246.17444 98.4453 3 1.852 MM 0.0486 18.75888 6.42801 0.4853 4 1.970 MM 0.0687 13.39437 3.24886 0.3465 5 2.157 MF 0.0438 3.09669 1.17808 0.0801 6 2.195 FM 0.0571 7.57808 2.21169 0.1961Totals : 3865.13763 1263.98098===================================================================== *** End of Report ***===========================================================Acq. Operator : Li Shan(LCMS-02) Seq. Line : 13Acq. Instrument : HY-LCMS-02 Location : P1-B-01Injection Date : 5/29/2015 10:18:18 AM Inj : 1Inj Volume : 3.000 µlAcq. Method : D:\AGLIENT 1260\DATA\20150529\20150529 2015-05-29 09-24-57\100-1000MS+3MIN- 1.5_(0.02%FA).MLast changed : 5/29/2015 9:24:57 AM by Li Shan(LCMS-02)Analysis Method : D:\AGLIENT 1260\METHOD\WASH-COL2-5MIN.M Last changed : 5/29/2015 12:45:14 PM by Li Shan(LCMS-02) (modified after loading)Catalo No : HY-11042 Batch#16355 A-RP-132Additional Info : Peak(s) manually integratedmin0.511.522.53100000200000300000400000500000600000700000800000900000 MSD1 TIC, MS File (D:\AGLIENT 1260\DATA\20150529\20150529 2015-05-29 09-24-57\BIZ2015-529-DJL2.D) ES-API, Pos, Sca1.672MS Signal: MSD1 TIC, MS File, ES-API, Pos, Scan, Frag: 50 Spectra averaged over upper half of peaks. Noise Cutoff: 1000 counts.Reportable Ion Abundance: > 10%.Retention Mol. Weight Time (MS) MS Area or Ion1.672 4227027 507.20 I 506.20 I 505.20 I 253.10 Im/z100200300400500600020406080100*MSD1 SPC, time=1.653:1.708 of D:\AGLIENT 1260\DATA\20150529\20150529 2015-05-29 09-24-57\BIZ2015-529-DJL2.D ES-API,Max: 318880507.2505.2253.1*** End of Report ***。
脂滴尼罗红染色
2
1． 开启荧光显微镜 2． 小心抽掉 25cm2 细胞培养瓶里的培养液
3． 加入 3 毫升用户自备的 HANK 平衡盐缓冲溶液或 PBS 缓冲溶液到细胞培养瓶，覆盖培养瓶表面
4． 小心抽掉清洗液
5． 加入
毫升 GENMED 染色工作液
6． 在 37℃培养箱孵育 10 分钟，避免光照
7． 在荧光显微镜下观察荧光细胞：激发波长 543nm，散发波长 598nm――显示强烈桔红色荧光细胞的为
产品内容
GENMED 染色液（Reagent A） （0.5 毫克/毫升） 产品说明书
1 毫升 1份
保存方式
保存 GENMED 染色液（Reagent A）在－20℃冰箱里，避免光照，有效保证 6 月
用户自备
HANK 平衡盐缓冲溶液（GMS12028）或 PBS 缓冲溶液（GMS12033）：用于清理细胞 胰蛋白酶乙二胺四乙酸混合液（GMS12024）：用于细胞脱离 完全细胞培养液（GMS12052）：用于细胞处理所需的培养基 15 毫升锥形离心管：用于细胞收集的存放 微型台式离心机：用于细胞沉淀收集 台式离心机：用于细胞沉淀收集 1.5 毫升离心管：用于细胞检测操作的容器 2 毫升离心管：用于染色工作液配制的容器 37℃培养箱：用于孵育反应物 比色皿：用于荧光定量分析 荧光显微镜：用于观察荧光细胞 荧光分光光度仪：用于定量检测荧光细胞和脂类产量
18．小心抽去上清液
19．加入 1 毫升用户自备的 HANK 平衡盐缓冲溶液或 PBS 缓冲溶液，充分混匀
20．（选择步骤）放进微型台式离心机离心 30 秒，速度为 16000g（或 13000RPM，例如 eppendorf 5415）
21．（选择步骤）小心抽去上清液
Agilent GeneJammer 转染试剂,货号 204131 - 化学品安全说明书
GeneJammer Transfection Reagent, Part Number 204131*************(24小时)化学品安全技术说明书GHS product identifier 应急咨询电话（带值班时间）::供应商/ 制造商:安捷伦科技贸易（上海）有限公司中国（上海）外高桥自由贸易试验区英伦路412号（邮编:200131)电话号码： 800-820-3278传真号码: 0086 (21) 5048 2818GeneJammer Transfection Reagent, Part Number 204131化学品的推荐用途和限制用途204131部件号:安全技术说明书根据 GB/ T 16483-2008 和 GB/ T 17519-2013GHS化学品标识:GeneJammer 转染试剂，货号 204131推荐用途:有关环境保护措施，请参阅第 12 节。
物质或混合物的分类根据 GB13690-2009 和 GB30000-2013紧急情况概述液体。
无资料。
无资料。
物理状态:颜色:气味:GHS危险性类别警示词:危险危险性说明::防范说明预防措施:P241 - 使用防爆的电气、通风、照明设备。
P242 - 使用不产生火花的工具。
P243 - 采取行动防止静电放电。
P233 - 保持容器密闭。
P264 - 作业后彻底清洗。
标签要素象形图易燃液体 - 类别 2严重眼损伤/眼刺激 - 类别 2AP305 + P351 + P338 - 如进入眼睛： 用水小心冲洗几分钟。
如戴隐形眼镜并可方便地取出，取出隐形眼镜。
继续冲洗。
P337 + P313 - 如仍觉眼刺激： 求医要么就诊。
安全储存:废弃处置:P501 - 处置内装物/容器按照地方/区域/国家/国际规章。
物理和化学危险高度易燃液体和蒸气。
健康危害::与物理,化学和毒理特性有关的症状皮肤接触食入吸入没有具体数据。
没有具体数据。
安捷伦产品目录
15
Real-Time PCR
16
Mx3000P QPCR System
17
Brilliant III Ultra-Fast SYBR Green QPCR and QRT-PCR Reagents
18
Brilliant III Ultra-Fast QPCR and QRT-PCR Reagents
Agilent / STRATAGENE
Agilent website: /genomics
Welgene | Agilent Stratagene
威健股份有限公司 | Stratagene 總代理
Table of Content
Table of Contents
/ XL1-Red Competent Cells SoloPack Gold Supercompetent Cells
/ TK Competent Cells Specialty Cells
/ Classic Cells / Fine Chemicals For Competent Cells
適用於 UNG 去汙染或 bisulphite
sequencing
適用於 TA Cloning
最高敏感性
取代傳統 Taq 的好選擇
-
2
威健股份有限公司 | Stratagene 總代理
PCR Enzyme & Instrument
Agilent SureCycler 8800
市場上領先的 cycling 速度和 sample 體積 10 ～ 100 μL 簡易快速可以選擇 96 well 和 384 well 操作盤 優秀的溫控設備讓各個 well 都能保持溫度的穩定 七吋的高解析度觸控螢幕讓操作上更為簡便 可以透過網路遠端操控儀器及監控儀器 Agilent 專業的技術支援可以幫助您應對各種 PCR 的問題
GC测定盐酸普拉克索中三乙胺残留量
GNE-477_DataSheet_MedChemExpress
Inhibitors, Agonists, Screening Libraries Data SheetBIOLOGICAL ACTIVITY:GNE–477 is a potent and efficacious dual PI3K/mTOR inhibitor with IC50 of 4 nM for PI3Kα, Kiapp is 21 nM for mTOR.IC50 value: 4 nM(PI3Kα); 21 nM(mTOR, Kiapp)Target: PI3K/mTOR inhibitorGNE–477 is a potent dual PI3K/mTOR inhibitor that displays desirable pharmacokinetic properties in each of three species studied.GNE–477 also exhibited stasis in a PC3 tumor growth inhibition study.PROTOCOL (Extracted from published papers and Only for reference)Animal administration [1]Female nu/nu mice were dosed with the GNE–477 HCl salt as a solution intraveinously (1 mg/kg) in 5% DMSO/5% cremophor and dosed orally as a solution in 80% PEG (5 mg/kg). Male rats were dosed with the GNE–477 TFA salt as a solution intraveinously (1mg/kg) in 5% DMSO/5% cremophor and dosed orally as a solution in 80% PEG (5 mg/kg). Male beagle dogs were dosed with the GNE–477 HCl salt as a solution intraveinously (1 mg/kg) in 10% HP–β–CD and dosed orally as a suspension in MCT (2 mg/kg).References:[1]. Heffron TP, et al. Identification of GNE–477, a potent and efficacious dual PI3K/mTOR inhibitor. Bioorg Med Chem Lett. 2010 Apr 15;20(8):2408–11.Product Name:GNE–477Cat. No.:HY-11042CAS No.:1032754-81-6Molecular Formula:C 21H 28N 8O 3S 2Molecular Weight:504.63Target:mTOR; PI3K Pathway:PI3K/Akt/mTOR; PI3K/Akt/mTOR Solubility:DMSO: < 9.2 mg/mLCaution: Product has not been fully validated for medical applications. For research use only.Tel: 609-228-6898 Fax: 609-228-5909 E-mail: tech@ Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA。
染色及助剂环保标准--2009年要求
邻氨基偶氮甲苯
97-56-3
４氨基联苯
92-67-1
５硝基邻甲苯胺
99-55-8
邻氨基苯甲醚
90-04-0
联苯胺
92-87-5
对氯苯胺
106-47-8
４氯邻甲苯胺
95-69-2
２甲氧基５甲基苯胺
120-71-8
２，４二氨基苯甲醚
615-05-4
４，４二氨基二苯甲烷
2682-20-4
五氯化苯酚(PCP)
87-86-5
未检出
§64 LFGB B 82.02.8(RL=0.5)
四氯苯酚(TeCP)
25167-83-3
富马酸二甲酯
624-49-7
禁止使用
溶剂萃取/GC-MS
IV) Bisphenol-A (BPA)双酚A
化学物质
CAS编号
产品最高限量
(ppm)
检检法
4,4dihydroxy2,2diphenylpropane
80-05-7
未检出
GC-MS/
LC-MS
V)抗光敏性致癌的分散染料及其它染料
化学物质
CAS编号
产品最高限量
检测法
(ppm)
分散染料
未检出
DIN54231单位：
毫克/升（RL：5）
分散蓝1
2475-45-8
分散蓝3
2475-46-9
分散蓝7
4098-71-9
游离型:1
封闭型: 100
四甲基苯二甲基二异氰酸酯
(TMXDI)
2778-42-9
游离型:1
封闭型: 100
甲苯异氰酸酯
(TDI)
GNE-477_SDS_MedChemExpress
Inhibitors, Agonists, Screening LibrariesSafety Data Sheet Revision Date:May-24-2017Print Date:May-24-20171. PRODUCT AND COMPANY IDENTIFICATION1.1 Product identifierProduct name :GNE-477Catalog No. :HY-11042CAS No. :1032754-81-61.2 Relevant identified uses of the substance or mixture and uses advised againstIdentified uses :Laboratory chemicals, manufacture of substances.1.3 Details of the supplier of the safety data sheetCompany:MedChemExpress USATel:609-228-6898Fax:609-228-5909E-mail:sales@1.4 Emergency telephone numberEmergency Phone #:609-228-68982. HAZARDS IDENTIFICATION2.1 Classification of the substance or mixtureNot a hazardous substance or mixture.2.2 GHS Label elements, including precautionary statementsNot a hazardous substance or mixture.2.3 Other hazardsNone.3. COMPOSITION/INFORMATION ON INGREDIENTS3.1 SubstancesSynonyms:GNE477; GNE 477Formula:C21H28N8O3S2Molecular Weight:504.63CAS No. :1032754-81-64. FIRST AID MEASURES4.1 Description of first aid measuresEye contactRemove any contact lenses, locate eye-wash station, and flush eyes immediately with large amounts of water. Separate eyelids with fingers to ensure adequate flushing. Promptly call a physician.Skin contactRinse skin thoroughly with large amounts of water. Remove contaminated clothing and shoes and call a physician.InhalationImmediately relocate self or casualty to fresh air. If breathing is difficult, give cardiopulmonary resuscitation (CPR). Avoid mouth-to-mouth resuscitation.IngestionWash out mouth with water; Do NOT induce vomiting; call a physician.4.2 Most important symptoms and effects, both acute and delayedThe most important known symptoms and effects are described in the labelling (see section 2.2).4.3 Indication of any immediate medical attention and special treatment neededTreat symptomatically.5. FIRE FIGHTING MEASURES5.1 Extinguishing mediaSuitable extinguishing mediaUse water spray, dry chemical, foam, and carbon dioxide fire extinguisher.5.2 Special hazards arising from the substance or mixtureDuring combustion, may emit irritant fumes.5.3 Advice for firefightersWear self-contained breathing apparatus and protective clothing.6. ACCIDENTAL RELEASE MEASURES6.1 Personal precautions, protective equipment and emergency proceduresUse full personal protective equipment. Avoid breathing vapors, mist, dust or gas. Ensure adequate ventilation. Evacuate personnel to safe areas.Refer to protective measures listed in sections 8.6.2 Environmental precautionsTry to prevent further leakage or spillage. Keep the product away from drains or water courses.6.3 Methods and materials for containment and cleaning upAbsorb solutions with finely-powdered liquid-binding material (diatomite, universal binders); Decontaminate surfaces and equipment by scrubbing with alcohol; Dispose of contaminated material according to Section 13.7. HANDLING AND STORAGE7.1 Precautions for safe handlingAvoid inhalation, contact with eyes and skin. Avoid dust and aerosol formation. Use only in areas with appropriate exhaust ventilation.7.2 Conditions for safe storage, including any incompatibilitiesKeep container tightly sealed in cool, well-ventilated area. Keep away from direct sunlight and sources of ignition.Recommended storage temperature:Powder-20°C 3 years4°C 2 yearsIn solvent-80°C 6 months-20°C 1 monthShipping at room temperature if less than 2 weeks.7.3 Specific end use(s)No data available.8. EXPOSURE CONTROLS/PERSONAL PROTECTION8.1 Control parametersComponents with workplace control parametersThis product contains no substances with occupational exposure limit values.8.2 Exposure controlsEngineering controlsEnsure adequate ventilation. Provide accessible safety shower and eye wash station.Personal protective equipmentEye protection Safety goggles with side-shields.Hand protection Protective gloves.Skin and body protection Impervious clothing.Respiratory protection Suitable respirator.Environmental exposure controls Keep the product away from drains, water courses or the soil. Cleanspillages in a safe way as soon as possible.9. PHYSICAL AND CHEMICAL PROPERTIES9.1 Information on basic physical and chemical propertiesAppearance Light yellow to yellow (Solid)Odor No data availableOdor threshold No data availablepH No data availableMelting/freezing point No data availableBoiling point/range No data availableFlash point No data availableEvaporation rate No data availableFlammability (solid, gas)No data availableUpper/lower flammability or explosive limits No data availableVapor pressure No data availableVapor density No data availableRelative density No data availableWater Solubility No data availablePartition coefficient No data availableAuto-ignition temperature No data availableDecomposition temperature No data availableViscosity No data availableExplosive properties No data availableOxidizing properties No data available9.2 Other safety informationNo data available.10. STABILITY AND REACTIVITY10.1 ReactivityNo data available.10.2 Chemical stabilityStable under recommended storage conditions.10.3 Possibility of hazardous reactionsNo data available.10.4 Conditions to avoidNo data available.10.5 Incompatible materialsStrong acids/alkalis, strong oxidising/reducing agents.10.6 Hazardous decomposition productsUnder fire conditions, may decompose and emit toxic fumes.Other decomposition products - no data available.11.TOXICOLOGICAL INFORMATION11.1 Information on toxicological effectsAcute toxicityClassified based on available data. For more details, see section 2Skin corrosion/irritationClassified based on available data. For more details, see section 2Serious eye damage/irritationClassified based on available data. For more details, see section 2Respiratory or skin sensitizationClassified based on available data. For more details, see section 2Germ cell mutagenicityClassified based on available data. For more details, see section 2CarcinogenicityIARC: No component of this product present at a level equal to or greater than 0.1% is identified as probable, possible or confirmed human carcinogen by IARC.ACGIH: No component of this product present at a level equal to or greater than 0.1% is identified as a potential or confirmed carcinogen by ACGIH.NTP: No component of this product present at a level equal to or greater than 0.1% is identified as a anticipated or confirmed carcinogen by NTP.OSHA: No component of this product present at a level equal to or greater than 0.1% is identified as a potential or confirmed carcinogen by OSHA.Reproductive toxicityClassified based on available data. For more details, see section 2Specific target organ toxicity - single exposureClassified based on available data. For more details, see section 2Specific target organ toxicity - repeated exposureClassified based on available data. For more details, see section 2Aspiration hazardClassified based on available data. For more details, see section 212. ECOLOGICAL INFORMATION12.1 ToxicityNo data available.12.2 Persistence and degradabilityNo data available.12.3 Bioaccumlative potentialNo data available.12.4 Mobility in soilNo data available.12.5 Results of PBT and vPvB assessmentPBT/vPvB assessment unavailable as chemical safety assessment not required or not conducted.12.6 Other adverse effectsNo data available.13. DISPOSAL CONSIDERATIONS13.1 Waste treatment methodsProductDispose substance in accordance with prevailing country, federal, state and local regulations.Contaminated packagingConduct recycling or disposal in accordance with prevailing country, federal, state and local regulations.14. TRANSPORT INFORMATIONDOT (US)This substance is considered to be non-hazardous for transport.IMDGThis substance is considered to be non-hazardous for transport.IATAThis substance is considered to be non-hazardous for transport.15. REGULATORY INFORMATIONSARA 302 Components:No chemicals in this material are subject to the reporting requirements of SARA Title III, Section 302.SARA 313 Components:This material does not contain any chemical components with known CAS numbers that exceed the threshold (De Minimis) reporting levels established by SARA Title III, Section 313.SARA 311/312 Hazards:No SARA Hazards.Massachusetts Right To Know Components:No components are subject to the Massachusetts Right to Know Act.Pennsylvania Right To Know Components:No components are subject to the Pennsylvania Right to Know Act.New Jersey Right To Know Components:No components are subject to the New Jersey Right to Know Act.California Prop. 65 Components:This product does not contain any chemicals known to State of California to cause cancer, birth defects, or anyother reproductive harm.16. OTHER INFORMATIONCopyright 2017 MedChemExpress. The above information is correct to the best of our present knowledge but does not purport to be all inclusive and should be used only as a guide. The product is for research use only and for experienced personnel. It must only be handled by suitably qualified experienced scientists in appropriately equipped and authorized facilities. The burden of safe use of this material rests entirely with the user. MedChemExpress disclaims all liability for any damage resulting from handling or from contact with this product.Caution: Product has not been fully validated for medical applications. For research use only.Tel: 609-228-6898 Fax: 609-228-5909 E-mail: tech@Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA。
拓扑替康结构式 -回复
拓扑替康结构式-回复拓扑替康（Tofacitinib）是一种属于JAK抑制剂的药物，用于治疗关节炎、银屑病和溃疡性结肠炎等自身免疫性疾病。
该药物的结构式如下所示：[拓扑替康结构式]拓扑替康属于一种小分子化合物，其化学名称为“3-{(3R，4R)-4-[(4-{(1E)-2-(5-氯-2-氧代苯基)乙-1-烯基}-1-苯基环己基)氨基]-3-甲基环己基}丙酸甲酯”。
它的化学式为C16H20N6O，分子量为312.37g/mol。
拓扑替康为无色结晶状固体，可溶于有机溶剂或水。
作用机制：拓扑替康通过抑制Janus激酶（JAK）的活性来发挥其治疗作用。
JAK是一类细胞内酪氨酸激酶，对细胞信号转导和调控起着重要作用。
通过抑制JAK的活性，拓扑替康可以干扰多个细胞因子途径的信号传递，从而调控免疫系统，减轻相关疾病的症状。
药物应用：拓扑替康已被美国食品药品监督管理局（FDA）批准用于治疗成人类风湿性关节炎、银屑病性关节炎、中度至重度溃疡性结肠炎以及活动性类风湿性关节炎。
它通常在其他治疗方法无效或无法耐受的情况下使用。
治疗效果：在临床试验中，拓扑替康已被证明能有效减少关节炎相关的关节疼痛、关节肿胀和关节运动受限等症状。
在银屑病和溃疡性结肠炎的治疗中，使用拓扑替康也能减少病情的恶化和复发。
注意事项：1. 在使用拓扑替康之前，患者应告知医生有关其过敏史、其他药物的使用情况以及存在的其他疾病，以便医生进行全面评估。
2. 拓扑替康可能会增加感染的风险。
在使用期间，患者应密切注意任何感染的症状，并及时向医生报告。
3. 服用拓扑替康可能导致一些不良反应，如头痛、腹泻、恶心、呕吐等。
如有不适，应立即告知医生。
总结：拓扑替康是一种抗关节炎和免疫性疾病药物，通过抑制JAK的活性，调控免疫系统，从而减轻相关疾病的症状。
尽管其可以有效改善患者的症状，但患者在使用该药物时需要密切关注可能产生的不良反应，并向医生报告任何异样症状。
通过科学的用药指导和临床监测，拓扑替康可以为患者提供更好的治疗效果。
(生物科技行业)密歇根大学生物系实验室的常用试剂配方
Table of ContentsLB Medium (1)NZ Medium (2)SM Buffer (3)SET Buffer (4)6X Prehyb Soln (5)10 X TBE (6)10 X TAE (7)20 X SSC (8)1% SDS, 0.2 M NaOH (9)14% PEG (8000), 2M NaCl, 10 mM MgSO4 (10)20% SDS (11)1.0 M Tris, pH 8.0, 1.5 M NaCl (12)10mM Tris-HCl, pH 7.5, 10mM MgSO4 (13)10 mM Tris, 50 mM EDTA, pH 7.5 (14)10 mM Tris-HCl, 1 mM EDTA, pH 7.5 (15)3 M Sodium Acetate, pH 4.8 (16)Electrophoresis dye (17)Labelling Stop dye (18)Sequencing gel dye (19)5% Acrylamide (20)6% Acrylamide in TBE, 50% Urea (21)40% Acrylamide (22)LB Medium (1 Liter)10g Bacto-tryptone5g Bacto-yeast extract10g NaClFor forty plates add 1% agar--1g. Autoclave media. When cool, add ampicillin and pour plates. For 1L of media, add 1.8 mL amp.NZ Medium (500 mL)5 g Bacto-tryptone2.5 g Bacto-yeast extract2.5 g NaCl1.25 g MgSO4For 20 plates add 1.2% agar--6g. Autoclave and pour plates at 50o CSM Buffer (1L)5.8 g NaCl1.2 g MgSo450 mL 1M Tris-HCl, pH 7.50.1 g Gelatin (doesn't dissolve)AutoclaveUsed for phage dilution and storage.SET Buffer50 mM Tris-HCl, pH 8.0, 50 mM EDTA, 20% w/v Sucroseto make 200mL:40 g Sucrose10 mL of 1M Tris20 mL of 0.5 M EDTA, disodium saltbring to 200 mL with H206X Prehybridization Solutionto make 500 mL300 mL ddH20150 mL 20X SSC50 mL 50X Denhardt's solution1 mL 0.5 M EDTA (disodium salt)2.5 mL 20% SDS6X refers to the concentration of SSC10X TBE Buffer (for polyacrylamide gels) to make one liter:60.75 g Tris3.7 g EDTA (tetrasodium salt)30 g Boric acid10X TAE Buffer (For agarose gels)to make one liter:48.20 g Tris6.75 g NaAce3.75 g EDTA (disodium salt)Adjust pH to 7.6 with acetic acid. (Approx. 20 mL)20X SSCto make one liter:175.3 g NaCl88.2 g NaCitrateadd water to bring volume to one liter.adjust to pH 7.0 with HCl.1% SDS, 0.2 M NaOHto make 100 mL:93 mL ddH205 mL 20% SDS2 mL 10 M NaOH14% PEG (8000), 2M NaCl, 10 mM MgSO4 to make one liter:140 g PEG117 g NaCl2.46 g MgSO4For use in phage DNA preparation.20% SDSto male 250 mL:50 g of SDS in a beakerAdd stir bar and H20 last.This solution will have to be heated for the SDS to dissolve.1.0 M Tris, pH 8.0, 1.5 M NaClto make one liter:121.1 g Trizma87.6 g NaClin a volume of water less than 1L. Adjust pH with HCl, then bring to 1L with H2010 mM Tris-HCl, pH 7.5, 10 mM MgSO4to make one liter:10 mL 1 M Tris-HCl2.46 g MgSO4for use in phage DNA preparation10 mM Tris, 50 mM EDTA, pH 7.5to make 200 mL:2 mL 1 M Tris20 mL 0.5 M EDTA (tetrasodium salt)178 mL ddH20adjust pH with HCl.10 mM Tris-HCl, 1 mM EDTA, pH 7.5to make 200 mL:2.0 mL 1 M Tris-HCl, pH 7.50.4 mL 0.5 M EDTA197.6 mL ddH203 M Sodium Acetate, pH 4.8to make one liter:408.1 g NaAce (trihydrate; gets cold in soln)about 700 mL H20adjust pH with glacial acetic acid (takes a lot)Measure tru pH by dilution with water; range will be between 4.8 and 5.5.Electrophoresis Dyeto make 4 mL:3 mL 50 mM EDTA, 10 mM Tris-HCl, pH 8.01 mL glycerol20 μL BPB10 μL Xylene cyanolStop dye for labelled probe1 mL 50 mM EDTA, 10 mM Tris, pH 7.5-8.5about 200 μl glyceroladd a few grains of blue dextran (8000)Sequencing gel dyefor approx 1 mL:1 mL formamide10 μL xylene cyanol10 μl BPB3 μL 10 M NaOH5% acrylamideto make 200 mL:20 mL 10X TBE25 mL 40% acrylamide155 mL H206% Acrylamide in TBE, 50% Ureato make 500 mL:50 mL 10X TBE75 mL 40% acrylamide250 g Ureabring to 500 mL with H2O40% Acrylamide (38:2 acrylamide:bis acrylamide) to make 200 mL:76 g acrylamide4 g bis acrylamidebring to 200 mL with H2O。
Y-27632_DataSheet_MedChemExpress
Inhibitors, Agonists, Screening Libraries Data SheetBIOLOGICAL ACTIVITY:Y–27632 is an ATP–competitive inhibitor of ROCK–I and ROCK–II , with K i of 220 nM and 300 nM for ROCK–I and ROCK–II , respectively.IC50 & Target: Ki: 220/300 nM (ROCK–I/II)[1]In Vitro: Y–27632 inhibits the ROCK family of kinases 100 times more potently than other kinases including protein kinase C,cAMP–dependent kinase and myosin light chain kinase. Y–27632 prolongs the lag time and delays the appearance of BrdU–labeled cells in a concentration–dependent manner, delays of about 1 and 4 h are noticed in the Swiss 3T3 cells treated with 10 and 100 μM Y–27632, respectively [1]. Y–27632 promotes neuronal differentiation of adipose tissue–derived stem cells (ADSCs). Compared to 1.0and 2.5 μM Y–27632 induced groups, percentages of neuroal–like cells achieved a peak in the 5.0 μM Y–27632 induced group [2].In Vivo: Y–27632 (5 and 10 mg/kg) significantly prolongs the onset time of myoclonic jerks when compare with saline group.Y–27632 (5 and 10 mg/kg) significantly prolongs the onset time of clonic convulsions when compare with saline group [3].Treatment with Dimethylnitrosamine (DMN) causes a significant decrease in rat body and liver weight (DMN–S group) compared with control animals (S–S group). Oral Y27632 (30 mg/kg) essentially prevents this DMN–induced rat body and liver weight loss (DMN–Y group)[4].PROTOCOL (Extracted from published papers and Only for reference)Kinase Assay:[1]Recombinant ROCK–I, ROCK–II, PKN, or citron kinase is expressed in HeLa cells as Myc–tagged proteins by transfection using Lipofectamine, and is precipitated from the cell lysates by the use of 9E10 monoclonal anti–Myc antibodycoupled to G protein–Sepharose. Recovered immunocomplexes are incubated with various concentrations of [32P]ATP and 10 mg of histone type 2 as substrates in the absence or presence of various concentrations of either Y–27632 or Y–30141 at 30°C for 30 min in a total volume of 30 μL of the kinase buffer containing 50 mM HEPES–NaOH, pH 7.4, 10 mM MgCl 2, 5 mM MnCl 2, 0.02% Briji 35, and 2 mM dithiothreitol. PKCa is incubated with 5 μM [32P]ATP and 200 μg/mL histone type 2 as substrates in the absence or presence of various concentrations of either Y–27632 or Y–30141 at 30°C for 10 min in a kinase buffer containing 50 mM Tris–HCl,pH 7.5, 0.5 mM CaCl 2, 5 mM magnesium acetate, 25 μg/mL phosphatidyl serine, 50 ng/mL 12–O–tetradecanoylphorbol–13–acetate and 0.001% leupeptin in a total volume of 30 μL. Incubation is terminated by the addition of 10 μL of 43 Laemmli sample buffer.After boiling for 5 min, the mixture is subjected to SDS–polyacrylamide gel electrophoresis on a 16% gel. The gel is stained withCoomassie Brilliant Blue, and then dried. The bands corresponding to histone type 2 are excised, and the radioactivity is measured [1]. Cell Assay: Y–27632 is dissolved in water and stored [1].[1]HeLa cells are plated at a density of 3×104 cells per 3.5–cm dish. The cells are cultured in DMEM containing 10% FBS in the presence of 10 mM Thymidine for 16 h. After the cells are washed with DMEM containing 10% FBS, they are cultured for an additional 8 h, and then 40 ng/mL of Nocodazole is added. After 11.5 h of theNocodazole treatment, various concentrations of Y–27632 (0–300 μM), Y–30141, or vehicle is added and the cells are incubated for another 30 min [1].Animal Administration: Y–27632 is dissolved in 0.9% NaCl (saline) (Mice)[3].Product Name:Y–27632Cat. No.:HY-10071CAS No.:146986-50-7Molecular Formula:C 14H 21N 3O Molecular Weight:247.34Target:ROCK; ROCK; ROCK Pathway:TGF–beta/Smad; Stem Cell/Wnt; Cell Cycle/DNA Damage Solubility:DMSO: ≥ 32 mg/mLY–27632 is dissolved in saline (final concentration 2%) (Rat)[4].[3][4]Mice[3]Male, inbred Swiss albino mice (2–3 months old) weighing 25–30 g are used. Mice are injected with a sub–convulsive dose of PTZ (35 mg/kg, i.p.) (on Mondays, Wednesdays and Fridays) of each week for a total of 11 injections. After each PTZ injection, mice are observed for 30 min and the occurrence of convulsive activity is recorded. After 30 min, the mice are then injected with either Fasudil (25 mg/kg, i.p.) or Y–27632 (5 mg/kg, i.p.) and returned to their home cages until the next injection. Control mice for Fasudil andY–27632 receives saline.Rat[4]Male Wistar Kind A rats (200–250 g) are used. DMN (1 g/mL) is diluted ten times with saline (final concentration 1%) and 10 mg/kg per day of DMN is injected intraperitoneally (i.p.) on the first 3 days of each week for 4 weeks. Y27632 is given orally once per day at a dose of 30 mg/kg for 4 weeks starting on the day of the first injection of DMN. The dose of 30 mg/kg corrects hypertension in several rat models without toxicity. Twenty rats are randomized into four experimental groups (n=5 in each group) as follows: (1) S–S (injection of saline i.p. and oral administration of saline); (2) S–Y (injection of saline i.p. and oral administration of Y27632); (3) DMN–S (DMN i.p. and oral administration of saline); (4) DMN–Y (DMN i.p. and oral administration of Y27632). The rats are weighed every week. They are sacrificed at the end of the fourth week and the liver is excised. In addition, a blood sample is taken immediately before the rats are sacrificed.References:[1]. Ishizaki T, et al. Pharmacological properties of Y–27632, a specific inhibitor of rho–associated kinases. Mol Pharmacol. 2000 May;57(5):976–83.[2]. Xue ZW, et al. Rho–associated coiled kinase inhibitor Y–27632 promotes neuronal–like differentiation of adult human adipose tissue–derived stem cells.Chin Med J (Engl). 2012 Sep;125(18):3332–5.[3]. Inan S, et al. Antiepileptic effects of two Rho–kinase inhibitors, Y–27632 and fasudil, in mice. Br J Pharmacol. 2008 Sep;155(1):44–51.[4]. Tada S, et al. A selective ROCK inhibitor, Y27632, prevents dimethylnitrosamine–induced hepatic fibrosis in rats. J Hepatol. 2001 Apr;34(4):529–36.Caution: Product has not been fully validated for medical applications. For research use only.Tel: 609-228-6898 Fax: 609-228-5909 E-mail: tech@Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA。